AbbVie Inc. (NYSE: ABBV) frequently makes financial headlines due to its strategic management of post-patent exclusivity challenges for its flagship immunology drug Humira, successful expansion of newer blockbuster immunology treatments like Skyrizi and Rinvoq, oncology pipeline developments, and its reliable history as a dividend king providing steady income returns to healthcare investors.